Multiple endogenous growth factor receptors on repair-related cells

Multiple endogenous growth factor receptors on repair-related cells refers to a collective therapeutic target concept primarily associated with regenerative medicine and wound healing treatments [1]. This target encompasses several receptor types, such as Platelet-Derived Growth Factor Receptors (PDGFR), Fibroblast Growth Factor Receptors (FGFR), and Epidermal Growth Factor Receptors (EGFR), which are expressed on cells like fibroblasts and keratinocytes [1][2]. Drugs targeting this system, such as the AMPK activator ENERGI-F703, do not typically bind the receptors directly but instead modulate intracellular pathways to increase receptor expression or sensitivity to the body's own (endogenous) growth factors [2][3]. This multi-receptor approach is designed to overcome the growth factor resistance often observed in chronic wounds, such as diabetic foot ulcers, by restoring the cells' ability to respond to natural healing signals [3][4]. By stimulating these receptors, the therapy promotes essential repair processes including cell proliferation, migration, and the synthesis of the extracellular matrix [1][5]. Sources: [1] Energi Biomedical (energi.tw); [2] ClinicalTrials.gov (NCT03611543); [3] AdisInsight (Springer Nature); [4] PubMed (PMID: 33454567); [5] StatPearls (Growth Factors in Wound Healing).

Other names

Endogenous growth factor receptorsRepair-related cell growth factor receptorsGrowth factor receptors in wound healing

Activation of Adenosine monophosphate-activated protein kinase (AMPK) to upregulate the expression and sensitivity of multiple endogenous growth factor receptors, such as PDGFR, FGFR, and EGFR, on cells involved in tissue repair.